Of the 26 companies that make up the Genome Technology Index, fully half were not public a year ago. At our editorial closing another dozen genome technology IPOs were in the pipeline.
We think an industry this dynamic deserves its own benchmark. So we’ve created one.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
